Description
Release form
coated tablets
Packing
100 pcs.
Pharmacological action srdlkant Immunode. The action of Rapamun is due to the suppression of T-cell activation by blocking Ca2 + -mediated and Ca2 + -independent intracellular signal transmission by binding to a specific cytosolic protein, immunophilin. Reduces the activity of T- and B-lymphocytes and suppresses rejection of an allogeneic transplant.
Indications
Prevention of transplant rejection (in adult patients with low to moderate immunological risk after kidney transplantation, in combination with corticosteroids and cyclosporine).
Contraindications
Pregnancy, lactation, childhood and adolescence, hypersensitivity to sirolimus.
Special instructions
Therapy should be performed by a physician with relevant experience in transplantology.
Composition
1 tablet contains 1 mg sirolimus
Dosage and administration of
Rapamun is taken orally. Recommended use in combination with corticosteroids and cyclosporine for 2-3 months. Supportive therapy, if necessary, can be continued in combination with corticosteroids without cyclosporine.
Initial therapy (within 2-3 months after transplantation): a saturating dose of 6 mg once for 48 hours after transplantation, then a maintenance dose of 2 mg / day. In the future, the dose should be chosen so that Cmin in the blood is in the range of 4-12 ng / ml (chromatographic method). Cmin of cyclosporine in the blood during the first 2-3 months after transplantation should be maintained at a level of 150-400 ng / ml (monoclonal method for determining the concentration).
Side effects of
From the lymphatic system: very often (10%) – lymphocele.
On the part of the body as a whole: often (1-10%) – impaired wound healing, swelling, development or exacerbation of fungal, viral and bacterial infections (including those caused by mycobacteria and the Epstein-Barr virus).
From the liver: possibly – hepatotoxicity, including fatal liver necrosis.
These side effects have been observed with combination therapy with sirolimus and cyclosporine.
Storage conditions
At a temperature not exceeding 25 ° C.
Active ingredient
Sirolimus
Conditions of release from drugstores
Prescription pdro8607277 Terms and conditions of vocational
lekarstvennaja form
tablets
